View Post

CRISPR may explain why so many experimental cancer drugs fail

In Clinical Trials by Barbara Jacoby

By: Sally Robertson, B.Sc. From: Researchers in the United States have discovered that many experimental cancer drugs may be missing their molecular targets and are instead succeeding in unintended ways, some of which could have toxic effects. Using the gene-editing tool CRISPR–Cas9 to investigate how ten cancer drugs interact with their protein target, the researchers found that the proteins …

View Post

It’s not time to freak out that Crispr will cause cancer—yet

In In The News by Barbara Jacoby

By: Katherine Ellen Foley From: The biotech industry is obsessed with Crispr, the molecular gene-editing technology capable of snipping out undesired bits of genetic material and, sometimes, replacing it with preferred DNA. Theoretically, Crispr capabilities could make curing previously incurable genetic conditions like cystic fibrosis a possibility for the first time. But on Monday (June 11), two new studies published side by sidein Nature Medicine …